Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Systemic polychemotherapy in the treatment of primary cutaneous lymphomas:a clinical follow-up study of 81 patients treated with COP or CHOP
Autore:
Fierro, MT; Quaglino, P; Savoia, P; Verrone, A; Bernengo, MG;
Indirizzi:
Univalyrin, Dept Med & Surg Specialties, Sect Dermatol 1, I-10126 Turin, It Univ Turin Turin Italy I-10126 lties, Sect Dermatol 1, I-10126 Turin, It
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 5-6, volume: 31, anno: 1998,
pagine: 583 - 588
SICI:
1042-8194(199811)31:5-6<583:SPITTO>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
B-CELL LYMPHOMAS; NON-HODGKINS-LYMPHOMA; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; RADIOTHERAPY; COMBINATION; VINCRISTINE; PREDNISONE;
Keywords:
primary cutaneous B-cell lymphoma; cutaneous T-cell lymphoma; polychemotherapy; COP regimen; CHOP regimen;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Bernengo, MG UnivI-10126 Dept Med & Surg Specialties, Sect Dermatol 1, ViaCherasco 23, Univ Turin Via Cherasco 23 Turin Italy I-10126 Cherasco 23,
Citazione:
M.T. Fierro et al., "Systemic polychemotherapy in the treatment of primary cutaneous lymphomas:a clinical follow-up study of 81 patients treated with COP or CHOP", LEUK LYMPH, 31(5-6), 1998, pp. 583-588

Abstract

The efficacy of systemic polychemotherapy in the treatment of primary cutaneous B-cell lymphomas (CBCL) or T-cell lymphomas (CTCL) is still controversial. A series of 81 patients (46 primary CBCL and 35 CTCL) were treated with COP or CHOP regimens. In primary CBCL, the overall objective response rate (RR) was 98 %, with an 89 % CR rate and a 33 % relapse-rate. Five-year disease-free survival was 70 %, 5-year survival 97 %. Patients with leg or widespread lesions showed a higher relapse-rate (55 % vs 26 %) than those with trunk or head lesions. The overall objective RR was 40 % in CTCL patients, with a 23 % CR rate; median response duration was 5.7 months, median survival 19 months. The results confirm both the good prognosis of primary CBCL and the efficacy of polichemotherapy. CHOP regimen is to be preferred to COP in as much as it reduces relapse rates. Conversely, there are no indications for the use of COP/CHOP regimens as first-line chemotherapy in CTCL patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 15:40:01